
CLAIMS

1. A compound represented by a structure of formula (X):

$$A_m\text{-}L\text{-}B \quad (X)$$

wherein

A is a radical of a fibroblast activation protein alpha (FAPα) ligand comprising a structure of formula (X-A):



(X-A)

wherein:

Q is aryl, heteroaryl, or heterocyclyl;

Z is a bond, substituted or unsubstituted C_1-C_3 alkylene, substituted or unsubstituted heteroalkylene, amino, -O-, or -S-;

T is substituted or unsubstituted methylene, substituted or unsubstituted amino, -O-, or -S-;

R^1 and R^2 are each independently selected from the group consisting of -H, -CN, -CHO, $-B(OH)_2$, -C(O)alkyl, -C(O)aryl-, -C=C-C(O)aryl, $-C{=}C\text{-}S(O)_2$aryl, $-CO_2H$, $-SO_3H$, $-SO_2NH_2$, $-PO_3H_2$, $-SO_2F$, $-CONH_2$, and 5-tetrazolyl;

R^3 and R^4 are each independently selected from the group consisting of -H, -OH, F, Cl, Br, I, $-C_{1\text{-}6}$alkyl, $-O\text{-}C_{1\text{-}6}$alkyl, and $-S\text{-}C_{1\text{-}6}$alkyl; and


R^5, R^6, R^7, and R^8 are each independently selected from group consisting of H, alkyl, and halo;

L is a linker connecting one or more A groups to B;

B is a radical of an optical dye, a photodynamic therapeutic agent, a radio-imaging agent, a radiotherapeutic agent, a chemotherapeutic agent, an antifibrotic agent, or an anticancer agent; and

m is 1-6.

2. The compound of claim 1, wherein A comprise a structure of formula (X-B):



(X-B)

wherein

Q is aryl, heteroaryl, or heterocyclyl;

T is substituted or unsubstituted methylene, substituted or unsubstituted amino, -O-, or -S-;

J is $C(R^J)_2$, wherein each R^J is independently H or alkyl, or both R^J are taken together to form oxo;













R^1 and R^2 are each independently selected from the group consisting of -H, -CN, -CHO, $-B(OH)_2$, -C(O)alkyl, -C(O)aryl-, -C=C-C(O)aryl, $-C=C-S(O)_2$aryl, $-CO_2H$, $-SO_3H$, $-SO_2NH_2$, $-PO_3H_2$, $-SO_2F$, $-CONH_2$, and 5-tetrazolyl;






R^3 and R^4 are each independently selected from the group consisting of - of -H, -OH, F, Cl, Br, I, $-C_{1-6}$alkyl, $-O-C_{1-6}$alkyl, and $-S-C_{1-6}$alkyl;

R^5, R^6, R^7, and R^8 are each independently selected from group consisting of H, alkyl, and halo; and

R^9, R^{10}, and R^{11} are each independently selected from group consisting of H, $-C_{1-6}$alkyl, $-C_{1-6}$haloalkyl, $-O-C_{1-6}$alkyl, $-S-C_{1-6}$ alkyl, F, Cl, Br, and I.

3. The compound of claim 1 or 2, wherein A is selected from the group consisting of:


,

,

,

,

,

,

,

,

,

,

,

,

4. The compound of any one of claims 1-3, wherein:

L is $(L^1)_o$-Y-$(L_2)_p$, wherein:

each L^1 is a first linker;

each L^2 is a second linker;

Y is a third linker;




o is an integer from 1-5; and

p is an integer from 1-5.


5. The compound of claim 4, wherein each L^1 and L^2 independently comprises one or more linker group, each linker group independently selected from the group consisting of alkyl(ene), heteroalkyl(ene), heterocycloalkyl(ene), heteroaryl, aryl, alkoxy, thioether, disulfide, carboxylic acid, anhydride, carbonate, carbamate, thioether, sugar, and peptide, or each L^1 and L^2 independently comprises one or more linker group, each linker group independently selected from the group consisting of polyethylene glycol (PEG), alkyl(ene), disulfide, amide, carboxylic acid, anhydride, carbonate, ester, carbamate, thioether, phenyl, and triazole.



6. The compound of claim 4 or 5, wherein Y has an amine core, an aromatic core, or an alkylene core.


7. The compound of claim 4 or 5, wherein L, L^1, L^2, or any combination thereof independently comprise i) at least one linker group having the following structure:


, 
, or 
,


wherein n is 0 to 10, ii) at least one linker group having the following structure:


, or iii) at least one linker group having the following structure:


, 
, or


, wherein n is 1 to 32.


8. The compound of any one of claims 1-7, wherein L has the following structure:


.

9. The compound of any one of claims 1-8, wherein i) the compound is an imaging agent and B is a radical of a fluorescent dye, ii) the compound is a chemotherapeutic agent and B is a


radical of an antifibrotic agent or an anticancer agent; or iii) B is radical of a phosphoinositide 3-kinase (PI3K) inhibitor.

10. The compound of any one of claims 1-9, wherein i) B has a structure of a radical of a compound represented by the following formula:



wherein:


X is selected from the group consisting of



and


,

or ii) B is a radical of a compound of the following structure:




.


11. A compound of the following structure:




or




or a compound of the following structure:




, or




, or a compound of the following structure:




,



,



, or



.

12. A pharmaceutical composition comprising a compound of any one of claims 1-11 and a pharmaceutically acceptable carrier.

13. A compound according to any one of claims 1-11 for use in treating cancer in a subject in need thereof wherein the cancer is optionally selected from the group consisting of fibrosarcoma, breast cancer, colorectal cancer, glioblastoma, squamous cell carcinoma, pancreatic cancer, and cervical cancer.

14. A compound according to any one of claims 1-11 for use in treating fibrosis in a subject in need thereof.


15. A conjugate represented by a structure of formula:

FAP-A-L-B

wherein

FAP is fibroblast activation protein alpha (FAPα), bound to the A group;

A is a radical of a fibroblast activation protein alpha (FAPα) ligand comprising a structure of formula (X-A):



(X-A)

wherein:

Q is aryl, heteroaryl, or heterocyclyl;

Z is a bond, substituted or unsubstituted C_1-C_3 alkylene, substituted or unsubstituted heteroalkylene, amino, -O-, or -S-;

T is substituted or unsubstituted methylene, substituted or unsubstituted amino, -O-, or -S-;

R^1 and R^2 are each independently selected from the group consisting of -H, -CN, -CHO, $-B(OH)_2$, -C(O)alkyl, -C(O)aryl-, -C=C-C(O)aryl, -C=C-$S(O)_2$aryl, $-CO_2H$, $-SO_3H$, $-SO_2NH_2$, $-PO_3H_2$, $-SO_2F$, $-CONH_2$, and 5-tetrazolyl;

R^3 and R^4 are each independently selected from the group consisting of -H, -OH, F, Cl, Br, I, -C_{1-6}alkyl, -O-C_{1-6}alkyl, and -S-C_{1-6}alkyl; and

R^5, R^6, R^7, and R^8 are each independently selected from group consisting of H, alkyl, and halo;

L is a linker connecting one or more A groups to B; and

B is a radical of an optical dye, a photodynamic therapeutic agent, a radio-imaging agent, a radiotherapeutic agent, a chemotherapeutic agent, an antifibrotic agent, or an anticancer agent.